127 related articles for article (PubMed ID: 15226656)
1. Medical predictive factors of glaucoma treatment costs.
Denis P; Lafuma A; Berdeaux G
J Glaucoma; 2004 Aug; 13(4):283-90. PubMed ID: 15226656
[TBL] [Abstract][Full Text] [Related]
2. Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany.
Lorenz K; Wolfram C; Breitscheidel L; Shlaen M; Verboven Y; Pfeiffer N
Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):2019-28. PubMed ID: 23624617
[TBL] [Abstract][Full Text] [Related]
3. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
Orme M; Collins S; Loftus J
J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
[TBL] [Abstract][Full Text] [Related]
4. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
[TBL] [Abstract][Full Text] [Related]
5. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands.
Oostenbrink JB; Rutten-van Mölken MP; Sluyter-Opdenoordt TS
J Glaucoma; 2001 Jun; 10(3):184-91. PubMed ID: 11442180
[TBL] [Abstract][Full Text] [Related]
6. The costs of treating glaucoma with combinations of topical drugs in Spain.
Neymark N; Buchholz P; Honrubia F; Kobelt G
Eur J Ophthalmol; 2008; 18(1):52-9. PubMed ID: 18203085
[TBL] [Abstract][Full Text] [Related]
7. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
[TBL] [Abstract][Full Text] [Related]
8. Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease.
Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR;
J Glaucoma; 2007 Aug; 16(5):471-8. PubMed ID: 17700290
[TBL] [Abstract][Full Text] [Related]
9. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
J Glaucoma; 2010 Mar; 19(3):199-206. PubMed ID: 19661825
[TBL] [Abstract][Full Text] [Related]
10. Resource use and costs for a glaucoma screening program in Austria: an 8-year review: a cost-consequence analysis based on the Salzburg-Moorfields Collaborative Glaucoma Study.
Hitzl W; Ortner C; Hornykewycz K; Grabner G; Reitsamer HA
Eur J Ophthalmol; 2006; 16(1):92-9. PubMed ID: 16496251
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Natt NK; Gupta A; Singh G; Singh T
Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
[TBL] [Abstract][Full Text] [Related]
12. [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].
Bron A; Nordmann JP; Baudouin C; Rouland JF; Kadi A; Sartral M
J Fr Ophtalmol; 2003 Nov; 26(9):895-903. PubMed ID: 14631273
[TBL] [Abstract][Full Text] [Related]
13. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.
Rouland JF; Le Pen C;
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S5-20. PubMed ID: 12948049
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
[TBL] [Abstract][Full Text] [Related]
16. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
Trese MGJ; Lewis AW; Blachley TS; Stein JD; Moroi SE
J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
[TBL] [Abstract][Full Text] [Related]
17. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.
Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC
J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
Schwartz GF; Reardon G
Surv Ophthalmol; 2004; 49(6):621-3; author reply 623-4. PubMed ID: 15530957
[No Abstract] [Full Text] [Related]
19. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
Kobelt-Nguyen G; Gerdtham UG; Alm A
J Glaucoma; 1998 Apr; 7(2):95-104. PubMed ID: 9559495
[TBL] [Abstract][Full Text] [Related]
20. [An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients].
Rouland JF; Peigne G; Sellem E; Renard JP; Williamson W; Filippi JM; Cohn H; Hamard P; Abellan P; Chagnon A; Malet F; Haye I
J Fr Ophtalmol; 2001 Mar; 24(3):233-43. PubMed ID: 11285438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
